Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Biocept Inc (BIOC)

Biocept Inc (BIOC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,960
  • Shares Outstanding, K 16,923
  • Annual Sales, $ 61,250 K
  • Annual Income, $ -2,820 K
  • 60-Month Beta 0.76
  • Price/Sales 0.26
  • Price/Cash Flow N/A
  • Price/Book 0.42
Trade BIOC with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.31
  • Most Recent Earnings -0.16 on 05/23/22
  • Next Earnings Date 11/21/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 281.31% ( -204.67%)
  • Historical Volatility 52.25%
  • IV Percentile 72%
  • IV Rank 18.90%
  • IV High 1,143.08% on 07/06/22
  • IV Low 80.53% on 08/16/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 7
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 1,862
  • Open Int (30-Day) 1,862

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.03
  • Growth Rate Est. (year over year) +3,329,900.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7170 +25.52%
on 09/26/22
1.0200 -11.76%
on 09/06/22
-0.1100 (-10.89%)
since 09/02/22
3-Month
0.7170 +25.52%
on 09/26/22
1.2000 -25.00%
on 08/16/22
-0.0542 (-5.68%)
since 07/05/22
52-Week
0.7170 +25.52%
on 09/26/22
4.3955 -79.52%
on 12/01/21
-2.9400 (-76.56%)
since 10/05/21

Most Recent Stories

More News
InnovAge Holding Corp. (INNV) Reports Q4 Loss, Lags Revenue Estimates

InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -200% and 0.74%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

INNV : 5.32 (-8.28%)
BIOC : 0.9000 (+1.81%)
HealthEquity (HQY) Misses Q2 Earnings Estimates

HealthEquity (HQY) delivered earnings and revenue surprises of -2.94% and 1.35%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?

HQY : 67.57 (+0.52%)
BIOC : 0.9000 (+1.81%)
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 89,550...

BIOC : 0.9000 (+1.81%)
Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it received a notice (the “Notice”) on August 17, 2022 from the Listing Qualifications...

BIOC : 0.9000 (+1.81%)
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the quarter ended June...

BIOC : 0.9000 (+1.81%)
RVL Pharmaceuticals PLC (RVLP) Reports Q2 Loss, Tops Revenue Estimates

RVL Pharmaceuticals PLC (RVLP) delivered earnings and revenue surprises of 20.83% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

RVLP : 2.16 (+1.89%)
BIOC : 0.9000 (+1.81%)
OncoCyte (OCX) Reports Q2 Loss, Misses Revenue Estimates

OncoCyte (OCX) delivered earnings and revenue surprises of 46.15% and 17.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

OCX : 0.7300 (-0.45%)
BIOC : 0.9000 (+1.81%)
Biocept Appoints RSM as Independent Auditor

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of RSM US LLP (“RSM”) as its independent registered public accounting...

BIOC : 0.9000 (+1.81%)
Biocept Appoints RSM as Independent Auditor

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of RSM US LLP (“RSM”) as its independent registered public accounting...

BIOC : 0.9000 (+1.81%)
Biocept to Hold Business Strategy Conference Call Today

Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call today, June 7, 2022, beginning at 4:00 p.m. Eastern time to discuss its re-focused and rationalized business strategy and to answer...

BIOC : 0.9000 (+1.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept,...

See More

Key Turning Points

3rd Resistance Point 0.9808
2nd Resistance Point 0.9615
1st Resistance Point 0.9227
Last Price 0.9000
1st Support Level 0.8646
2nd Support Level 0.8453
3rd Support Level 0.8065

See More

52-Week High 4.3955
Fibonacci 61.8% 2.9903
Fibonacci 50% 2.5563
Fibonacci 38.2% 2.1222
Last Price 0.9000
52-Week Low 0.7170

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar